ClinicalTrials.gg
RecruitingNCT06318078Updated Mar 19, 2024

Buikwe Electronic Community Health Information System Impact Study

An interventional study of eCHIS in Malaria, Diarrhea and Pneumonia, sponsored by Malaria Consortium. Recruiting at 1 site in Uganda. Open to participants aged 3 Months to 59 Months. Per ClinicalTrials.gov, last updated 2024-03-19.

Sponsored by Malaria Consortium · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,140
Allocation
Randomized
Ages
3 Months to 59 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Malaria by Malaria Consortium — 3 open to participants now, 9 under way, 2 of them phase 3. Malaria · Malaria Consortium.

Started
2023
with 3 others
No phase
3 of 10
1 open now
Registered
9th of 10
by date

Among the 10 studies in Malaria by Malaria Consortium, this one is one of 4 that started in 2023, is one of 3 with no phase, and was the 9th registered.

Malaria

1,186 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

3 of the 10 studies in Malaria by Malaria Consortium are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 3 Months to 59 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Malaria by Malaria Consortium, or all of them as a file.
02

Study summary

The purpose of the study is to investigate the impact of the eCHIS intervention on key child health outcomes.

Read the detailed description

Following national guidelines, 2 VHTs per village will be supported to provide the full eCHIS community health package. In total 856 VHTs in Buikwe district will have been trained and equipped with the national strategy and operational guidelines on eCHIS as well as the VHT full package (iCCM+ and VHT basic package (reproductive health, immunization, nutrition) guidelines. The VHTs will be equipped with mobile devices and iCCM supplies to start the management of community-based health among children aged five years within their respective communities. A cross-sectional cluster randomized controlled trial (cRCT) will be used to establish study outcomes in children under 5 years in the intervention and control areas using mixed methods (qualitative and quantitative) of data collection.

A total sample size of 1,140 children under five: 570 children under five, per arm, was scientifically determined for the study. During data collection, several quality control measures will be applied to ensure the data recorded reflect the facts, responses, observations, and events. A standard operating procedure (SOP) with roles and responsibilities of the data collectors will be prepared to ensure standardized methods for capturing data. After endline data collection, difference-in-differences (DID) analysis will be done to derive an estimate of the intervention effect on odds of the study outcomes.

Results will be disseminated through agreed peer-review publications and international conferences. Malaria Consortium Uganda will work with relevant stakeholders at the Ministry of Health and Medic Mobile to disseminate findings nationally and throughout the study district.

03

Conditions studied

  • Malaria
  • Diarrhea
  • Pneumonia
04

Who can participate

Ages eligible
3 Months to 59 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Children between 3-59 months,

      • Being resident in the study area,
      • Consent to participate in the study obtained,
      • Willingness and ability of the child's guardians to comply with the study protocol for the duration of the study including attending a designated health centre if their child has malaria symptoms during the data collection period.

Exclusion criteria

Exclusion Criteria:

  • Children aged below 3 months and above 59 months
  • Children resident outside the study areas
  • Those who have not consented to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,140 participants (estimated)

Study arms

  • Experimental
    Intervention

    570 children will be allocated to the intervention arm and children in this arm will be assessed using the eCHIS digital tool.

    Other: eCHIS

  • No intervention
    Control

    570 children will be allocated to the intervention arm and children in this arm will be assessed using the standard care and paper based tools.

Interventions

  • OthereCHIS

    The electronic Community health Information System (eCHIS) is a Government of Uganda owned application used by community health workers for quality health assessments and improved reporting. The eCHIS intervention allows for the registration of longitudinal profiles for client centered care as well as provides care guidance to aid decision making. For its users, the app has a task tab for schedule management and dashboards for performance help management and impact tracking by supervisors. This app is interoperable with national reporting tools such as DHIS2. The app has ten workflows including registration of households and new persons, death reporting, iCCM assessment, treatment and referral follow up, stock monitoring, data synchronization, pregnancy registration, ANC danger signs and follow up, family planning registration, and screening (tuberculosis, hypertension, sickle cell, tobacco use and net use).

06

What researchers measure

Primary outcomes

  1. Out Patient Department attendance (due to malaria, pneumonia and diarrhoea)

    Attendance measured through baseline and endline surveys

    Time frame: Over 1 year

  2. Hospitalisation (due to malaria, pneumonia and diarrhoea)

    Attendance measured through baseline and endline surveys

    Time frame: Over 1 year

  3. malaria related mortality in the community and health facilities

    Malaria related mortality measured through routine data

    Time frame: Over 1 year

07

Study locations

1 of 1 sites recruiting
  • Buikwe
    Buikwe, Uganda
    Recruiting
    • John Baptist Bwanika, MD · Contact
    • John Baptist Bwanika, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Apr 2024, 4 months after the start.

Of 96 non-industry interventional studies with no phase under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 4 months is below that.

Counting every sponsor, half of 102 studies reached it within 23 months; a quarter within 8 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Mar 19, 2024
StartActual
Dec 1, 2023
Primary completionEst.
Apr 2024
CompletionEst.
Jul 2024
Last update
Mar 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06318078
Lead sponsor
Malaria Consortium
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Dec 1, 2023
Primary completion
Apr 2024 (estimated)
Completion
Jul 2024 (estimated)
Last update
Mar 19, 2024

Study contacts

John Baptist Bwanika
Contact
j.bwanika@malariaconsortium.org
+256 772744390
Kevin Baker
Contact
k.baker@malariaconsortium.org
07811266539044
John Baptist Bwanika
principal investigator · Malaria Consortium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion